Clinical trial
Irinotecan Study For Cervical Cancer
NCT00136955 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00136955 |
|---|---|
| Title | Irinotecan Study For Cervical Cancer |
| Official title | An Open Labeled, Single-Arm, Multicentre Phase II Study To Evaluate The Efficacy And Safety Of Weekly Irinotecan Plus Cisplatin As First-Line Chemotherapy For Advanced Or Recurrent Squamous Cell Carcinoma Of The Uterine Cervix |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Uterine Cervical Neoplasms |
| Intervention type | Drug |
| Interventions | Irinotecan |
| Enrollment | 41 |
| Start date | Jun 1, 2004 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Aug 29, 2005 |
| Last update posted | Jun 19, 2015 |
| Countries | Taiwan |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: